首页> 美国卫生研究院文献>AAPS PharmSciTech >Conjugation of Hot-Melt Extrusion with High-Pressure Homogenization: a Novel Method of Continuously Preparing Nanocrystal Solid Dispersions
【2h】

Conjugation of Hot-Melt Extrusion with High-Pressure Homogenization: a Novel Method of Continuously Preparing Nanocrystal Solid Dispersions

机译:热熔挤出与高压均质化的共轭:连续制备纳米晶体固体分散体的新方法。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Over the past few decades, nanocrystal formulations have evolved as promising drug delivery systems owing to their ability to enhance the bioavailability and maintain the stability of poorly water-soluble drugs. However, conventional methods of preparing nanocrystal formulations, such as spray drying and freeze drying, have some drawbacks including high cost, time and energy inefficiency, traces of residual solvent, and difficulties in continuous operation. Therefore, new techniques for the production of nanocrystal formulations are necessary. The main objective of this study was to introduce a new technique for the production of nanocrystal solid dispersions (NCSDs) by combining high-pressure homogenization (HPH) and hot-melt extrusion (HME). Efavirenz (EFZ), a Biopharmaceutics Classification System class II drug, which is used for the treatment of human immunodeficiency virus (HIV) type I, was selected as the model drug for this study. A nanosuspension (NS) was first prepared by HPH using sodium lauryl sulfate (SLS) and Kollidon® 30 as a stabilizer system. The NS was then mixed with Soluplus® in the extruder barrel, and the water was removed by evaporation. The decreased particle size and crystalline state of EFZ were confirmed by scanning electron microscopy, zeta particle size analysis, and differential scanning calorimetry. The increased dissolution rate was also determined. EFZ NCSD was found to be highly stable after storage for 6 months. In summary, the conjugation of HPH with HME technology was demonstrated to be a promising novel method for the production of NCSDs.
机译:在过去的几十年中,由于纳米晶体制剂具有增强生物利用度并保持水溶性差的药物的稳定性的能力,因此已发展成为有希望的药物递送系统。然而,制备纳米晶体制剂的常规方法,例如喷雾干燥和冷冻干燥,具有一些缺点,包括高成本,时间和能量效率低,痕量残留溶剂以及难以连续操作。因此,需要用于生产纳米晶体制剂的新技术。这项研究的主要目的是介绍一种通过结合高压均质化(HPH)和热熔挤出(HME)来生产纳米晶体固体分散体(NCSD)的新技术。 Efavirenz(EFZ),一种用于治疗I型人类免疫缺陷病毒(HIV)的生物药物分类系统II类药物,被选作该研究的模型药物。首先通过HPH使用月桂基硫酸钠(SLS)和30作为稳定剂系统,制备纳米悬浮液(NS)。然后在挤出机机筒中将NS与Soluplus®混合,并通过蒸发除去水。通过扫描电子显微镜,ζ粒度分析和差示扫描量热法证实了EFZ的减小的粒度和结晶状态。还确定了增加的溶解速率。发现EFZ NCSD在存储6个月后非常稳定。总之,HPH与HME技术的结合被证明是生产NCSD的有前途的新方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号